Ipsen Biopharmaceuticals, Inc.
1 Main Street
About Ipsen Biopharmaceuticals, Inc.
Ipsen (Euronext: IPN; ADR: IPSEY) is a global, biopharmaceutical group focused on innovation and specialty care. The group develops and commercializes innovative medicines in three key therapeutic areas - Oncology, Neuroscience and Rare Diseases. At Ipsen, we focus our resources, investments and energy on discovering, developing and commercializing new therapeutic options to provide hope for patients whose lives are challenged by difficult-to-treat diseases. Ipsen's North American operations and headquarters are located in Cambridge, Massachusetts, where our fully integrated biopharmaceutical team across External Innovation and Partnering, Research & Development (R&D), Manufacturing and Commercial collaborate. Cambridge is home to Ipsen's third global hub, in addition to R&D centers in Paris-Saclay in France and Oxford in the United Kingdom. With additional offices in Basking Ridge, N.J. and Mississauga, Ontario, Ipsen employs approximately 600 people in North America. For more information on Ipsen in North America, please visit www.ipsenus.com or www.ipsen.ca.
590 articles about Ipsen Biopharmaceuticals, Inc.
Ipsen Delivers Sales Growth in the First Nine Months of 2020 Despite the Impact of COVID-19 and Confirms Its 2020 Full Year Guidance
Ipsen, a global specialty-driven biopharmaceutical group, announced sales for the third quarter of 2020.
Ipsen to Present 12 Abstracts at the 11th World Congress for Neurorehabilitation (WCNR) Virtual Congress Taking Place Jointly With the 35th Congress of the French Society of Physical and Rehabilitation Medicine (SOFMER)1-13
Ipsen announced the presentation of 12 abstracts during the 11th World Congress for Neurorehabilitation, taking place virtually between 7-11 October 2020.1-13
Ipsen announced the appointment of Philippe Lopes-Fernandes as Executive Vice President, Chief Business Officer, effective 1 October 2020.
ESMO 2020: Cabometyx® (cabozantinib) in Combination With Opdivo® (nivolumab) Demonstrates Significant Survival Benefits in Patients With Advanced Renal Cell Carcinoma in Pivotal Phase III CheckMate -9ER Trial
Cabometyx® in combination with Opdivo® showed superior overall survival and doubled median progression-free survival and objective response rate versus sunitinib, and had a favorable safety profile
ESMO 2020: Phase II CLARINET FORTE Results Show Increasing Dose Frequencies of Somatuline® Autogel® (lanreotide) Allows Patients with NETs to Delay Treatment Escalation by up to 8.3 Months
Increasing the dose frequency of lanreotidefrom monthly to bi-monthly achieved a progression-free survival of 8.3 months in patients with progressive midgut neuroendocrine tumors (NETs) and 5.6 months in patients with progressive pancreatic NETs
Ipsen Showcases Commitment to Patient-centric Advances in Oncology With Record Number of Abstracts to Be Presented at ESMO 2020 Virtual Congress
17 abstracts1 to be shared, spanning a wide range of different cancer types, therapies and clinical study and real-world evidence designs
Ipsen to Present New Insights at ASBMR for Potential Treatment of Ultra-rare Disease Fibrodysplasia Ossificans Progressiva (FOP), Including Global Phase III MOVE Trial Results
Seven presentations represent Ipsen’s largest presence to date at ASBMR, the world’s leading scientific organization for bone health research
8/27/2020Biopharma and life sciences companies from around the globe share updates on their business practices and pipelines.
Ipsen, a global specialty-driven biopharmaceutical group, announced financial results for the first half of 2020.
Ipsen Announces Updated Indication for Dysport® (abobotulinumtoxinA) for the Treatment of Spasticity in Children
Ipsen Biopharmaceuticals, an affiliate of Ipsen (Euronext: IPN; ADR: IPSEY), announced today that the United States Food and Drug Administration (FDA) has approved the expanded use of Dysport® (abobotulinumtoxinA) in pediatric patients
Ipsen Joins Clinical Collaboration to Evaluate Cabozantinib (CABOMETYX®) Plus Atezolizumab in Metastatic Non-Small Cell Lung Cancer and Metastatic Castration-Resistant Prostate Cancer
Clinical collaboration marks an important milestone in partnership with Exelixis to further develop cabozantinib
Ipsen, announces that it has appointed an investment services provider to purchase 450,000 Ipsen SA shares, or about 0.54% of the share capital, over a maximum period of 6 months.
Ipsen Demonstrates Continued Commitment to Rare Diseases With Eight Abstracts Accepted at ENDO 2020 Published in the Journal of the Endocrine Society
Data published evaluates fibrodysplasia ossificans progressiva (FOP) natural disease progression
Ipsen announced that its Board of Directors has appointed David Loew as its new Chief Executive Officer and as Board member.
After four years as head of Sanofi’s vaccines division, David Loew is departing the pharma giant to take on a new role – chief executive officer of Paris-based Ipsen, effective July 1.
Ipsen: New Surveys Show Over 80% of Patients with Spasticity and Cervical Dystonia Treated with Botulinum Toxin-A Experience Debilitating Symptom Recurrence
Over 400 patients with spasticity or cervical dystonia responded to online surveys evaluating the disease burden and the impact on their personal and professional lives
Ipsen enters into an option agreement with IRICoR and Université de Montréal for a discovery-stage oncology program
Ipsen, a global specialty-driven biopharmaceutical group, IRICoR, a pan-Canadian research commercialization center focused on drug discovery, and Université de Montréal, announced they entered into an option agreement by which Ipsen would acquire an exclusive license for the worldwide rights to a high-value oncology program.
Continued momentum with Q1 2020 Group sales growth of 9.6% as reported, or 8.7%1 at constant exchange rates
Ipsen Announces Positive Topline Results From Pivotal Phase III CheckMate -9ER Trial Evaluating CABOMETYX® (cabozantinib) in Combination with Opdivo® (nivolumab) in Previously Untreated Advanced Renal Cell Carcinoma
Ipsen Announces Positive Topline Results From Pivotal Phase III CheckMate -9ER Trial Evaluating CABOMETYX ® (cabozantinib) in Combination with Opdivo® (nivolumab) in Previously Untreated Advanced Renal Cell Carcinoma Study met primary endpoint of significantly improving progression-free survival, and secondary endpoints of overall survival and objective response rate vs. sunitinib CABOMETYX in combination with Opdivo demonstrates clinically m
The biopharmaceutical group Ipsen has answered call of the Institut Pasteur and announces a donation of €2 million dedicated to COVID-19 research.